-
Spinal Cerebrospinal Fluid Leak Mimicking a Cerebellopontine Angle Tumor. JAMA Neurol. (IF 20.4) Pub Date : 2024-12-16 Wouter I Schievink,Ferdinand K Hui
-
Quality Improvement Intervention for Reducing Acute Treatment Times in Ischemic Stroke: A Cluster Randomized Clinical Trial. JAMA Neurol. (IF 20.4) Pub Date : 2024-12-16 Daniël Hansen,Sanne J den Hartog,Nikki van Leeuwen,Jelis Boiten,Wouter Dinkelaar,Pieter J van Doormaal,Frank Eijkenaar,Bart J Emmer,Adriaan C G M van Es,H Zwenneke Flach,Rob Gons,M Heleen den Hertog,Farshad Imani,Paula M Janssen,Hans Kortman,Nyika D Kruyt,Laurien S Kuhrij,Christiaan van der Leij,T H Rob Lo,Aad van der Lugt,Geert Lycklama À Nijeholt,Jasper M M Martens,Paul J Nederkoorn,Jurgen Piet,Michel
Importance Efficient care processes are crucial to minimize treatment delays and improve outcome after endovascular thrombectomy (EVT) in patients with ischemic stroke. A potential means to improve care processes is performance feedback. Objective To evaluate the effect of performance feedback to hospitals on treatment times for EVT. Design, Setting, and Participants This cluster randomized clinical
-
Neurological Pupil Index and Intracranial Hypertension in Patients With Acute Brain Injury: A Secondary Analysis of the ORANGE Study. JAMA Neurol. (IF 20.4) Pub Date : 2024-12-09 Matteo Petrosino,Elisa Gouvêa Bogossian,Paola Rebora,Stefania Galimberti,Randall Chesnut,Pierre Bouzat,Mauro Oddo,Fabio Silvio Taccone,Giuseppe Citerio,
Importance Invasive intracranial pressure (ICP) is the standard of care in patients with acute brain injury (ABI) with impaired consciousness. The Neurological Pupil Index (NPi) obtained by automated pupillometry is promising for noninvasively estimating ICP. Objectives To evaluate the association between repeated NPi and invasive ICP values. Design, Setting, and Participants This study is a secondary
-
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis JAMA Neurol. (IF 20.4) Pub Date : 2024-12-09 Eline M. E. Coerver, Wing Hee Fung, Janet de Beukelaar, Willem H. Bouvy, Leo R. Canta, Oliver H. H. Gerlach, Elske Hoitsma, Erwin L. J. Hoogervorst, Brigit A. de Jong, Nynke F. Kalkers, Zoé L. E. van Kempen, Harry Lövenich, Caspar E. P. van Munster, Bob W. van Oosten, Joost Smolders, Anke Vennegoor, Esther M. P. E. Zeinstra, Mar Barrantes-Cepas, Gijs Kooij, Menno M. Schoonheim, Birgit I. Lissenberg-Witte
ImportanceIncreasing numbers of people with multiple sclerosis (MS) use disease-modifying therapy (DMT). Long-term stable disease while taking such medications provides a rationale for considering DMT discontinuation given patient burden, costs, and potential adverse effects of immunomodulating therapy.ObjectiveTo investigate whether first-line DMT can be safely discontinued in patients with long-term
-
Protecting Neural Data Privacy-First, Do No Harm. JAMA Neurol. (IF 20.4) Pub Date : 2024-12-02 Sean Pauzauskie,Jared Genser,Rafael Yuste
-
β-Blocker Use and Delayed Onset and Progression of Huntington Disease JAMA Neurol. (IF 20.4) Pub Date : 2024-12-02 Jordan L. Schultz, Amy C. Ogilvie, Lyndsay A. Harshman, Peg C. Nopoulos
ImportanceHuntington disease (HD) is characterized by motor, cognitive, and psychiatric decline. β-Blockers may play a therapeutic role by decreasing enhanced sympathetic tone in HD.ObjectiveTo evaluate the impact of β-blockers on the timing of motor diagnosis onset and progression of HD symptoms.Design, Setting, and ParticipantsThis observational, longitudinal multicenter study used the Enroll-HD
-
β-Amyloid Positron Emission Tomography Use Across Medicare Administrative Contractor Regions JAMA Neurol. (IF 20.4) Pub Date : 2024-12-02 Zachary A. Marcum, Dominic Nunag, Adam P. Bress, Jeremy Pruzin
This cross-sectional study assesses variation in β-amyloid positron emission tomography (PET) use among Medicare beneficiaries with mild cognitive impairment or dementia by Medicare Administrative Contractor region.
-
Disease Severity Staging System for NOTCH3-Associated Small Vessel Disease, Including CADASIL JAMA Neurol. (IF 20.4) Pub Date : 2024-11-29 Gido Gravesteijn, Julie W. Rutten, Minne N. Cerfontaine, Remco J. Hack, Yi-Chu Liao, Amy A. Jolly, Stéphanie Guey, Shao-Lun Hsu, Jae-young Park, Yun Yuan, Anna Kopczak, Nicola Rifino, Sam J. Neilson, Anna Poggesi, Md Manjurul Islam Shourav, Satoshi Saito, Hiroyuki Ishiyama, Ana Domínguez Mayoral, Renata Nogueira, Elena Muiño, Pia Andersen, Nicola De Stefano, Gustavo Santo, Nontapat Sukhonpanich, Francesco
ImportanceTypical cysteine-altering NOTCH3 (NOTCH3cys) variants are highly prevalent (approximately 1 in 300 individuals) and are associated with a broad spectrum of small vessel disease (SVD), ranging from early-onset stroke and dementia (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy [CADASIL]) to nonpenetrance. A staging system that captures the full NOTCH3-SVD
-
Equipping AI for Unbiased and Inclusive Neurology JAMA Neurol. (IF 20.4) Pub Date : 2024-11-25 Nina F. Schor
This Viewpoint advocates for inclusive artificial intelligence (AI) training and iterative testing and cautions against the uncritical adoption of AI engines that are trained on median patient groups and exclude the outlier groups that neurology regularly treats.
-
Neuropsychological Outcomes in 6-Year-Old Children of Women With Epilepsy: A Prospective Nonrandomized Clinical Trial. JAMA Neurol. (IF 20.4) Pub Date : 2024-11-25 Kimford J Meador,Morris J Cohen,David W Loring,Abigail G Matthews,Carrie Brown,Chelsea P Robalino,Andrea Carmack,Angela K Birnbaum,Paula E Voinescu,Elizabeth E Gerard,Laura A Kalayjian,Evan R Gedzelman,Julie Hanna,Jennifer Cavitt,Maria Sam,Sean Hwang,Alison M Pack,Jacqueline A French,Jeffrey J Tsai,Cora Taylor,Page B Pennell,
Importance Antiseizure medications (ASMs) are potential teratogens commonly prescribed for multiple indications. ASM fetal exposure can impair neurodevelopment. Folate improves pregnancy outcomes, but higher doses may pose risks. Objectives To compare the outcomes of 6-year-old children of women with epilepsy (WWE) vs those of healthy women (HW), and assess the association of outcomes to third-trimester
-
Vertebral Web and Embolic Stroke JAMA Neurol. (IF 20.4) Pub Date : 2024-11-25 Kiran Waqar, Praveen Kesav, Seby John
This case report describes a female individual in her 30s with headache and vertigo; examination revealed acute embolic infarcts and a lesion on the vertebral artery.
-
Psychiatric Comorbidities in Persons With Epilepsy Compared With Persons Without Epilepsy JAMA Neurol. (IF 20.4) Pub Date : 2024-11-25 Churl-Su Kwon, Ali Rafati, Ruth Ottman, Jakob Christensen, Andres M. Kanner, Nathalie Jetté, Charles R. Newton
ImportanceSeveral psychiatric disorders have been found to occur more frequently in persons with epilepsy (PWE) than in persons without epilepsy.ObjectiveTo summarize the prevalence of 20 psychiatric disorders in PWE compared with persons without epilepsy.Data SourcesThe search included records from inception to February 2024 in Ovid, MEDLINE, Embase, and PsycINFO.Study SelectionPublished epidemiological
-
Current and Future Roles of Chimeric Antigen Receptor T-Cell Therapy in Neurology JAMA Neurol. (IF 20.4) Pub Date : 2024-11-25 Fatme Seval Ismail, Marco Gallus, Sven G. Meuth, Hideho Okada, Hans-Peter Hartung, Nico Melzer
ImportanceAdvancements in molecular engineering have facilitated the creation of engineered T cells that express synthetic receptors, termed chimeric antigen receptors (CARs). This is promising not only in cancer treatment but also in addressing a spectrum of other conditions. This review provides a comprehensive overview of the current approaches and future potential of CAR T-cell therapy in the field
-
Wildfire Smoke Exposure and Incident Dementia JAMA Neurol. (IF 20.4) Pub Date : 2024-11-25 Holly Elser, Timothy B. Frankland, Chen Chen, Sara Y. Tartof, Elizabeth Rose Mayeda, Gina S. Lee, Alexander J. Northrop, Jacqueline M. Torres, Tarik Benmarhnia, Joan A. Casey
ImportanceLong-term exposure to total fine particulate matter (PM2.5) is a recognized dementia risk factor, but less is known about wildfire-generated PM2.5, an increasingly common PM2.5 source.ObjectiveTo assess the association between long-term wildfire and nonwildfire PM2.5 exposure and risk of incident dementia.Design, Setting, and ParticipantsThis open cohort study was conducted using January
-
Trends in Gender, Racial, and Ethnic Representation Among US Neurology Faculty. JAMA Neurol. (IF 20.4) Pub Date : 2024-11-18 Chia-Chen Tsai,Chen Hu,Jeffrey Ding,Esther Bui,Aleksandra Pikula,Thalia S Field,Sabeen Tiwana,Javed Siddiqi,Faisal Khosa
-
AI Devices in Neurology-Moving From Diagnosis to Prognosis. JAMA Neurol. (IF 20.4) Pub Date : 2024-11-18 James M Hillis,Edward R Scheffer Cliff,Kerstin N Vokinger
-
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease JAMA Neurol. (IF 20.4) Pub Date : 2024-11-18 Stephen Salloway, Jakub Wojtowicz, Nicola Voyle, Christopher A. Lane, Gregory Klein, Marco Lyons, Simona Rossomanno, Francesca Mazzo, Szofia Bullain, Frederik Barkhof, Tobias Bittner, Andres Schneider, Michael Grundman, Roxana Aldea, Mercè Boada, Janice Smith, Rachelle Doody
ImportanceData from 2 phase 3 studies of gantenerumab, GRADUATE I/II, and their open-label extensions represent a resource to further characterize amyloid-related imaging abnormalities (ARIA), including long-term sequelae.ObjectivesTo describe the characteristics of ARIA and risk factors and clinical consequences of ARIA-edema (ARIA-E).Design, Setting, and ParticipantsSecondary data collection from
-
Clinical Presentation, Investigation Findings, and Outcomes of IgG4-Related Pachymeningitis JAMA Neurol. (IF 20.4) Pub Date : 2024-11-18 Sara Terrim, João Vitor Mahler, Flávio Vieira Marques Filho, Leandro Tavares Lucato, Henrique Mayrink Giardini, Tarso Adoni, Guilherme Diogo Silva
ImportanceImmunoglobulin G4 (IgG4)–related disease is an increasingly recognized fibroinflammatory condition that can involve multiple organs, including the pachymeninges. The understanding of IgG4-related pachymeningitis (IgG4-RP) remains limited because of its rarity and the predominance of knowledge derived from case reports and case series.ObjectiveTo systematically review and synthesize the clinical
-
Gantenerumab in Dominantly Inherited Alzheimer Disease. JAMA Neurol. (IF 20.4) Pub Date : 2024-11-11 Nunzio Pomara,Bruno Pietro Imbimbo
-
Gantenerumab in Dominantly Inherited Alzheimer Disease-Reply. JAMA Neurol. (IF 20.4) Pub Date : 2024-11-11 Olivia Wagemann,Eric McDade,Randall J Bateman
-
Frailty Trajectories Preceding Dementia in the US and UK JAMA Neurol. (IF 20.4) Pub Date : 2024-11-11 David D. Ward, Jonny P. Flint, Thomas J. Littlejohns, Isabelle F. Foote, Marco Canevelli, Lindsay M. K. Wallace, Emily H. Gordon, David J. Llewellyn, Janice M. Ranson, Ruth E. Hubbard, Kenneth Rockwood, Erwin Stolz
ImportanceAn accessible marker of both biological age and dementia risk is crucial to advancing dementia prevention and treatment strategies. Although frailty is a candidate for that role, the nature of the relationship between frailty and dementia is not well understood.ObjectiveTo clarify the temporal relationship between frailty and incident dementia by investigating frailty trajectories in the
-
Epileptiform Electrographic Patterns After Cardiac Arrest JAMA Neurol. (IF 20.4) Pub Date : 2024-11-11 Andrea O. Rossetti, Sarah Benghanem
This Viewpoint challenges conventional clinical practice that eschews pharmacological intervention for comatose patients with epileptiform abnormalities after cardiac arrest using evidence from the Treatment of Electroencephalographic Status Epilepticus after Cardiopulmonary Resuscitation (TELSTAR) trial.
-
Immediate or Delayed Statin in Acute Atherosclerotic Ischemia. JAMA Neurol. (IF 20.4) Pub Date : 2024-11-04 Anastasios Kollias,Konstantinos G Kyriakoulis,Kyriakos Dimitriadis
-
Immediate or Delayed Statin in Acute Atherosclerotic Ischemia-Reply. JAMA Neurol. (IF 20.4) Pub Date : 2024-11-04 Ying Gao,Yuesong Pan,Yilong Wang
-
Deferiprone in Alzheimer Disease JAMA Neurol. (IF 20.4) Pub Date : 2024-11-04 Scott Ayton, David Barton, Bruce Brew, Amy Brodtmann, Roger Clarnette, Patricia Desmond, David Devos, Kathryn A. Ellis, Amir Fazlollahi, Caroline Fradette, Anita M. Y. Goh, Pawel Kalinowski, Christopher Kyndt, Rosalyn Lai, Yen Ying Lim, Paul Maruff, Terence J. O’Brien, Christopher Rowe, Olivier Salvado, Peter W. Schofield, Michael Spino, Fernando Tricta, Aaron Wagen, Robert Williams, Michael Woodward
ImportanceInterventions that substantially slow neurodegeneration are needed to address the growing burden of Alzheimer disease (AD) to societies worldwide. Elevated brain iron observed in AD has been associated with accelerated cognitive decline and may be a tractable drug target.ObjectiveTo investigate whether the brain-permeable iron chelator deferiprone slows cognitive decline in people with AD
-
Remembering the Physician’s Humanity—Physicians Are Humans Too JAMA Neurol. (IF 20.4) Pub Date : 2024-11-04 Noriko Anderson
This essay describes the microaggressions and burnout faced by physicians and the importance of boundaries to preserve physicians’ humanity and well-being.
-
Alzheimer Disease as a Clinical-Biological Construct—An International Working Group Recommendation JAMA Neurol. (IF 20.4) Pub Date : 2024-11-01 Bruno Dubois, Nicolas Villain, Lon Schneider, Nick Fox, Noll Campbell, Douglas Galasko, Miia Kivipelto, Frank Jessen, Bernard Hanseeuw, Mercè Boada, Frederik Barkhof, Agneta Nordberg, Lutz Froelich, Gunhild Waldemar, Kristian Steen Frederiksen, Alessandro Padovani, Vincent Planche, Christopher Rowe, Alexandre Bejanin, Agustin Ibanez, Stefano Cappa, Paulo Caramelli, Ricardo Nitrini, Ricardo Allegri
ImportanceSince 2018, a movement has emerged to define Alzheimer disease (AD) as a purely biological entity based on biomarker findings. The recent revision of the Alzheimer Association (AA) criteria for AD furthers this direction. However, concerns about a purely biological definition of AD being applied clinically, the understanding of AD by society at large, and the translation of blood-based biomarkers
-
Mobile Stroke Units-Time for Legislation and Remuneration. JAMA Neurol. (IF 20.4) Pub Date : 2024-12-01 Babak B Navi,Pooja Khatri
-
Neonatal Neurocritical Care Training—The Time Has Come JAMA Neurol. (IF 20.4) Pub Date : 2024-10-28 Christopher D. Smyser, Donna M. Ferriero, Laura R. Ment
This Viewpoint describes the advent of neonatal neurocritical care training, the data supporting the need and its efficacy, and the ways this training can optimize outcomes for vulnerable patients and their families.
-
Mobile Stroke Unit Management in Patients With Acute Ischemic Stroke Eligible for Intravenous Thrombolysis JAMA Neurol. (IF 20.4) Pub Date : 2024-10-28 Brian Mac Grory, Jie-Lena Sun, Brooke Alhanti, Jay Lusk, Fan Li, Opeolu Adeoye, Karen Furie, David Hasan, Steven Messe, Kevin N. Sheth, Lee H. Schwamm, Eric E. Smith, Deepak L. Bhatt, Gregg C. Fonarow, Jeffrey L. Saver, Ying Xian, James Grotta
ImportanceClinical trials have suggested that prehospital management in a mobile stroke unit (MSU) improves functional outcomes in patients with acute ischemic stroke who are potentially eligible for intravenous thrombolysis, but there is a paucity of real-world evidence from routine clinical practice on this topic.ObjectiveTo determine the association between prehospital management in an MSU vs standard
-
A Clown With Traumatic Brain Injury JAMA Neurol. (IF 20.4) Pub Date : 2024-10-28 S. Thomas Carmichael
This essay describes the efforts patients might make to hold onto their humanity in the midst of an absurd world: being in the emergency department with a neurological injury.
-
Development and Validation of a Clinical Score to Predict Epilepsy After Cerebral Venous Thrombosis. JAMA Neurol. (IF 20.4) Pub Date : 2024-12-01 Erik Lindgren,Liqi Shu,Naaem Simaan,Katarzyna Krzywicka,Maria A de Winter,Mayte Sánchez van Kammen,Jeremy Molad,Piers Klein,Hen Hallevi,Rani Barnea,Mirjam R Heldner,Sini Hiltunen,Diana Aguiar de Sousa,José M Ferro,Antonio Arauz,Jukka Putaala,Marcel Arnold,Thanh N Nguyen,Christoph Stretz,Turgut Tatlisumak,Katarina Jood,Shadi Yaghi,Ronen R Leker,Jonathan M Coutinho,,Maryam Mansour,Patrícia Canhão,Esme
Importance One of 10 patients develop epilepsy in the late phase after cerebral venous thrombosis (CVT) diagnosis but predicting the individual risk is difficult. Objective To develop and externally validate a prognostic score to estimate the individual risk of post-CVT epilepsy. Design, Setting, and Participants This observational cohort study included both retrospective and prospective patients enrolled
-
Hearing Loss, Incident Parkinson Disease, and Treatment With Hearing Aids JAMA Neurol. (IF 20.4) Pub Date : 2024-10-21 Lee E. Neilson, Kelly M. Reavis, Jack Wiedrick, Gregory D. Scott
ImportanceThe risk of developing Parkinson disease (PD) after objective hearing loss is unknown. PD studies using self-reported hearing loss are insensitive, and objective data are lacking.ObjectiveTo examine the association of hearing loss with incident PD in US veterans and its effect modification by well-established prodromal conditions and hearing aids.Design, Setting, and ParticipantsThis cohort
-
Risk of Inflammatory Central Nervous System Diseases After Tumor Necrosis Factor–Inhibitor Treatment for Autoimmune Diseases JAMA Neurol. (IF 20.4) Pub Date : 2024-10-21 Wenhui Xie, Yunchuang Sun, Wei Zhang, Nanbo Zhu, Shiyu Xiao
ImportanceTumor necrosis factor (TNF) inhibitors have been used extensively to treat various autoimmune diseases. However, there are ongoing debates about the risk of inflammatory central nervous system (CNS) disease events following TNF inhibitor therapy, as well as uncertainty about how this risk varies across different autoimmune diseases or TNF-blocking agents.ObjectiveTo evaluate the risk of inflammatory
-
Genome Sequencing After Exome Sequencing in Pediatric Epilepsy JAMA Neurol. (IF 20.4) Pub Date : 2024-10-21 Alissa M. D’Gama, Wanqing Shao, Lacey Smith, Hyun Yong Koh, Maya Davis, Julia Koh, Brandon T. Oby, Cesar I. Urzua, Beth Rosen Sheidley, Shira Rockowitz, Annapurna Poduri
This cohort study examined the yield and use of genome sequencing after nondiagnostic exome sequencing for pediatric patients with unexplained epilepsy between August 2018 and May 2023.
-
Collaborative Dementia Care During the New Therapeutic Era. JAMA Neurol. (IF 20.4) Pub Date : 2024-12-01 Katherine L Possin,Jeffrey M Burns,Brent P Forester
-
Multisite Skin Biopsies vs Cerebrospinal Fluid for Prion Seeding Activity in the Diagnosis of Prion Diseases JAMA Neurol. (IF 20.4) Pub Date : 2024-10-14 Zhong-yun Chen, Qi Shi, Kang Xiao, Yu Kong, Dong-lin Liang, Yi-hao Wang, Rong Min, Jing Zhang, Zhen Wang, Hong Ye, Ran Gao, Min Chu, Hai-tian Nan, De-ming Jiang, Jun-jie Li, Lin Wang, Wen-Quan Zou, Li-yong Wu, Xiao-ping Dong
ImportanceRecent studies have revealed that autopsy skin samples from cadavers with prion diseases (PRDs) exhibited a positive prion seeding activity similar to cerebrospinal fluid (CSF). It is worthwhile to validate the findings with a large number of biopsy skin samples and compare the clinical value of prion seeding activity between skin biopsies and concurrent CSF specimens.ObjectiveTo compare
-
Directly Isolated Allogeneic Virus–Specific T Cells in Progressive Multifocal Leukoencephalopathy JAMA Neurol. (IF 20.4) Pub Date : 2024-10-07 Nora Möhn, Lea Grote-Levi, Mike P. Wattjes, Agnes Bonifacius, Dennis Holzwart, Franziska Hopfner, Sandra Nay, Sabine Tischer-Zimmermann, Mieke Luise Saßmann, Philipp Schwenkenbecher, Kurt-Wolfram Sühs, Nima Mahmoudi, Clemens Warnke, Julian Zimmermann, David Hagin, Lilia Goudeva, Rainer Blasczyk, Armin Koch, Britta Maecker-Kolhoff, Britta Eiz-Vesper, Günter Höglinger, Thomas Skripuletz
ImportanceProgressive multifocal leukoencephalopathy (PML) is a life-threatening viral infection with no approved antiviral treatment.ObjectiveTo determine whether restoring the compromised immune system of patients with PML with directly isolated allogeneic virus–specific (DIAVIS) T cells is a promising therapeutic strategy, especially if other curative options are absent.Design, Setting, and ParticipantsA
-
Barriers to Tofersen Therapy for Variant SOD1-Mediated ALS JAMA Neurol. (IF 20.4) Pub Date : 2024-10-07 Stanley H. Appel, Jason R. Thonhoff
This Viewpoint advocates for the accelerated adoption of tofersen therapy to treat patients with variant SOD1-mediated amyotrophic lateral sclerosis (ALS) and describes the current barriers to treatment.
-
Peripheral-Type Facial Paralysis and Unilateral Hemisphere Hemorrhage. JAMA Neurol. (IF 20.4) Pub Date : 2024-12-01 Chunyong Chen,Jian Zhang,Jingjing Huang
-
Antiseizure Medications and Cardiovascular Events in Older People With Epilepsy JAMA Neurol. (IF 20.4) Pub Date : 2024-09-30 Jimmy Li, Nathan A. Shlobin, Roland D. Thijs, Marie-Pierre Sylvestre, Colin B. Josephson, Charles Deacon, Mark R. Keezer
ImportanceHow epilepsy may promote cardiovascular disease remains poorly understood.ObjectiveTo estimate the odds of new-onset cardiovascular events (CVEs) over 6 years in older people with vs without epilepsy, exploring how enzyme-inducing antiseizure medications (EIASMs) and traditional cardiovascular risk factors mediate these odds.Design, Setting, and ParticipantsThis was a prospective cohort study
-
Brain Networks for Cortical Atrophy and Responsive Neurostimulation in Temporal Lobe Epilepsy JAMA Neurol. (IF 20.4) Pub Date : 2024-09-30 Sara Larivière, Frédéric L. W. V. J. Schaper, Jessica Royer, Raúl Rodríguez-Cruces, Ke Xie, Jordan DeKraker, Alexander Ngo, Ella Sahlas, Judy Chen, Shahin Tavakol, William Drew, Mae Morton-Dutton, Aaron E. L. Warren, Sheena R. Baratono, John D. Rolston, Yifei Weng, Andrea Bernasconi, Neda Bernasconi, Luis Concha, Zhiqiang Zhang, Birgit Frauscher, Boris C. Bernhardt, Michael D. Fox
ImportanceDrug-resistant temporal lobe epilepsy (TLE) has been associated with hippocampal pathology. Most surgical treatment strategies, including resection and responsive neurostimulation (RNS), focus on this disease epicenter; however, imaging alterations distant from the hippocampus, as well as emerging data from responsive neurostimulation trials, suggest conceptualizing TLE as a network disorder
-
Risks of Expanded Medicare Coverage of Carotid Artery Stenting JAMA Neurol. (IF 20.4) Pub Date : 2024-09-30 Caitlin W. Hicks, Frank J. Veith
This Viewpoint describes the potential harms associated with increased coverage of carotid artery stenting by the Centers for Medicare & Medicaid Services.
-
Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation. JAMA Neurol. (IF 20.4) Pub Date : 2024-09-23 Moniek Maarse,David J Seiffge,David J Werring,Lucas V A Boersma,,,Errol W Aarnink,Nicolai Fierro,Patrizio Mazzone,Alessandro Beneduce,Claudio Tondo,Alessio Gasperetti,Radoslaw Pracon,Marcin Demkow,Kamil Zielinski,Ole de Backer,Kasper Korsholm,Jens Erik Nielsen-Kudsk,Rodrigo Estévez-Loureiro,Berenice Caneiro-Queija,Tomás Benito-González,Armando Pérez de Prado,Luis Nombela-Franco,Pablo Salinas,David
Importance Patients with atrial fibrillation (AF) who have ischemic stroke despite taking oral anticoagulation therapy (OAT) have a very high risk of recurrence. Left atrial appendage occlusion (LAAO) is a mechanical stroke prevention strategy that may provide additional protection in patients with thromboembolic events under OAT. Objective To compare percutaneous LAAO with continuing OAT alone regarding
-
Four-Repeat Tau Seeding in the Skin of Patients With Progressive Supranuclear Palsy. JAMA Neurol. (IF 20.4) Pub Date : 2024-09-23 Ivan Martinez-Valbuena,M Carmela Tartaglia,Susan H Fox,Anthony E Lang,Gabor G Kovacs
-
Perceived CTE and Suicidality-Is Perception Reality? JAMA Neurol. (IF 20.4) Pub Date : 2024-09-23 Michael L Alosco,Kristine Yaffe
-
Antiseizure Medication Use and Outcomes After Suspected or Confirmed Acute Symptomatic Seizures JAMA Neurol. (IF 20.4) Pub Date : 2024-09-23 Sahar F. Zafar, Adithya Sivaraju, Clio Rubinos, Neishay Ayub, Phillip O. Awodutire, Zachary McKee, Pradeep Chandan, MarieElena Byrnes, Sakhi A. Bhansali, Hunter Rice, Arthor Smith-Ayala, Muhammad Adnan Haider, Elizabeth Tveter, Natalie Erlich-Malona, Fernando Ibanhes, Alexis DeMarco, Skylar Lewis, Monica B. Dhakar, Vineet Punia
ImportanceAntiseizure medications (ASMs) are frequently prescribed for acute symptomatic seizures and epileptiform abnormalities (EAs; eg, periodic or rhythmic patterns). There are limited data on factors associated with ASM use and their association with outcomes.ObjectivesTo determine factors associated with ASM use in patients with confirmed or suspected acute symptomatic seizures undergoing continuous
-
Perceived Chronic Traumatic Encephalopathy and Suicidality in Former Professional Football Players JAMA Neurol. (IF 20.4) Pub Date : 2024-09-23 Rachel Grashow, Douglas P. Terry, Grant L. Iverson, Heather DiGregorio, Inana Dairi, Cheyenne Brown, Paula S. Atkeson, Alicia J. Whittington, LeRoy Reese, Jonathan H. Kim, Niki Konstantinides, Herman A. Taylor, Frank E. Speizer, Daniel H. Daneshvar, Ross D. Zafonte, Marc G. Weisskopf, Aaron L. Baggish
ImportanceParticipation in American-style football (ASF) has been linked to chronic traumatic encephalopathy neuropathological change (CTE-NC), a specific neuropathologic finding that can only be established at autopsy. Despite being a postmortem diagnosis, living former ASF players may perceive themselves to have CTE-NC. At present, the proportion and clinical correlates of living former professional
-
Comorbidity and Disease Activity in Multiple Sclerosis JAMA Neurol. (IF 20.4) Pub Date : 2024-09-18 Amber Salter, Samantha Lancia, Kaarina Kowalec, Kathryn C. Fitzgerald, Ruth Ann Marrie
ImportanceMultiple studies suggest that comorbidity worsens clinically relevant outcomes in multiple sclerosis (MS), including the severity of disability at diagnosis and rate of disability worsening after diagnosis. However, less is known regarding the association of comorbidity with measures of disease activity, such as relapse rate and magnetic resonance imaging lesion accrual, which are relevant
-
Intracranial Pressure Elevation and MOGAD JAMA Neurol. (IF 20.4) Pub Date : 2024-09-16 Nanthaya Tisavipat, Natthapon Rattanathamsakul, Abdul-Rahman Salman, Laura Cacciaguerra, Sean J. Pittock, Eoin P. Flanagan, John J. Chen
This cross-sectional study examines the frequency of increased intracranial pressure and its association with myelin oligodendrocyte glycoprotein antibody-associated disease in patients of various ages.
-
Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations JAMA Neurol. (IF 20.4) Pub Date : 2024-09-16 Le H. Hua, Andrew J. Solomon, Silvia Tenembaum, Antonio Scalfari, Àlex Rovira, Kevin Rostasy, Scott D. Newsome, Ruth Ann Marrie, Melinda Magyari, Orhun Kantarci, Bernhard Hemmer, Cheryl Hemingway, Mary Pat Harnegie, Jennifer S. Graves, Jeffrey A. Cohen, Riley Bove, Brenda Banwell, John R. Corboy, Emmanuelle Waubant
ImportanceWhile the typical onset of multiple sclerosis (MS) occurs in early adulthood, 2% to 10% of cases initially present prior to age 18 years, and approximately 5% after age 50 years. Guidance on approaches to differential diagnosis in suspected MS specific to these 2 age groups is needed.ObservationsThere are unique biological factors in children younger than 18 years and in adults older than
-
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine JAMA Neurol. (IF 20.4) Pub Date : 2024-09-16 Stewart J. Tepper, David W. Dodick, Michel Lanteri-Minet, David Dolezil, Raquel Gil-Gouveia, Christian Lucas, Karolina Piasecka-Stryczynska, Gyöngyi Szabó, Daniel D. Mikol, Mahan Chehrenama, Denise E. Chou, Yiping Yang, Gabriel Paiva da Silva Lima
ImportancePatients with chronic migraine and medication overuse headaches (CM-MOH) represent a particularly burdened subpopulation. This trial provides first, to our knowledge, American Academy of Neurology class I evidence for a preventive therapy in CM-MOH.ObjectiveTo assess erenumab efficacy and safety in patients with nonopioid CM-MOH.Design, Settings, and ParticipantsThis randomized, double-blind
-
How Is the X Chromosome Involved in Alzheimer Disease? JAMA Neurol. (IF 20.4) Pub Date : 2024-10-01 Rachel F Buckley,Mabel Seto
-
Role of the X Chromosome in Alzheimer Disease Genetics JAMA Neurol. (IF 20.4) Pub Date : 2024-09-09 Michael E. Belloy, Yann Le Guen, Ilaria Stewart, Kennedy Williams, Joachim Herz, Richard Sherva, Rui Zhang, Victoria Merritt, Matthew S. Panizzon, Richard L. Hauger, J. Michael Gaziano, Mark Logue, Valerio Napolioni, Michael D. Greicius
ImportanceThe X chromosome has remained enigmatic in Alzheimer disease (AD), yet it makes up 5% of the genome and carries a high proportion of genes expressed in the brain, making it particularly appealing as a potential source of unexplored genetic variation in AD.ObjectivesTo perform the first large-scale X chromosome–wide association study (XWAS) of AD.Design, Setting, and ParticipantsThis was a
-
A Unique Case of Opioid-Induced Myoclonus. JAMA Neurol. (IF 20.4) Pub Date : 2024-09-03 Augusto Rachão,Pedro Pereira,Miguel Grunho
-
Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease JAMA Neurol. (IF 20.4) Pub Date : 2024-09-03 Young Nam Kwon, Boram Kim, Jun-Soon Kim, Kyung Seok Park, Da-Young Seo, Hyunjin Kim, Eun-Jae Lee, Young-Min Lim, Hyunjin Ju, Yeon Hak Chung, Ju-Hong Min, Tai-Seung Nam, Sooyoung Kim, Eunhee Sohn, Kyong Jin Shin, Jin Myoung Seok, Sunyoung Kim, Jong Seok Bae, Sukyoon Lee, Seong-il Oh, Yu Jin Jung, Jinseok Park, Seung Hyun Kim, Ki Hoon Kim, Ho Jin Kim, Jae Ho Jung, Seong-Joon Kim, Seung Woo Kim, Myoung-jin
ImportanceA proportion of people with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) have a relapsing disease course and persistent anti–myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) seropositivity. Few studies have investigated whether treatment of the first MOGAD attack is associated with the long-term disease course and/or MOG-IgG seronegative conversion
-
Endovascular vs Medical Management of Acute Basilar Artery Occlusion: A Secondary Analysis of a Randomized Clinical Trial. JAMA Neurol. (IF 20.4) Pub Date : 2024-10-01 Rui Li,Chunrong Tao,Jun Sun,Chao Zhang,Pengfei Xu,Yamei Yin,Hongxing Han,Guangxiong Yuan,Tao Cui,Peiyang Zhou,Wenhuo Chen,Guoyong Zeng,Yuwen Li,Zhengfei Ma,Chuanqing Yu,Junfeng Su,Zhiming Zhou,Zhongjun Chen,Li Wang,Cong Luo,Xiaozhong Jing,Anmo Wang,Nan Shen,Mohamad Abdalkader,Thanh N Nguyen,Adnan I Qureshi,Jeffrey L Saver,Raul G Nogueira,Wei Hu,
Importance In several randomized clinical trials, endovascular thrombectomy led to better functional outcomes than conventional treatment at 90 days poststroke in patients with acute basilar artery occlusion. However, the long-term clinical outcomes of these patients have not been well delineated. Objective To evaluate 1-year clinical outcomes in patients with acute basilar artery occlusion following
-
Association of Cardiovascular Events With Spouse's Subsequent Dementia. JAMA Neurol. (IF 20.4) Pub Date : 2024-10-01 Toshiaki Komura,Yusuke Tsugawa,Elizabeth Rose Mayeda,M Maria Glymour,Kosuke Inoue
-
Sex Differences in Case-Fatality Rates of Stroke-Reply. JAMA Neurol. (IF 20.4) Pub Date : 2024-10-01 Daniela Renedo,Kevin N Sheth
-
JAMA Neurology Editorial Fellowship-Call for Applicants. JAMA Neurol. (IF 20.4) Pub Date : 2024-10-01 S Andrew Josephson